REACH3: Ruxolitinib in Steroid Refractory cGvHD

Opinion
Video

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Related Content
Precision Medicine Implemented in the Community Oncology Setting

Precision Medicine Implemented in the Community Oncology Setting

Marcus Neubauer, MD;Sagran Moodley
March 15th 2024
Article

Technology plays a pivotal role in enhancing precision medicine within cancer care.

Read More

Yazan Madanat, MD, an expert on MDS

Key Updates in Lower-Risk MDS

Yazan Madanat, MD
February 5th 2024
Article

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.

Read More

Evolving Treatments in Newly Diagnosed Multiple Myeloma (NDMM)

Evolving Treatments in Newly Diagnosed Multiple Myeloma (NDMM)

Peter Voorhees, MD
January 25th 2024
Article

In this companion article, Dr Peter Voorhees provides insights into effective management of patients with newly diagnosed multiple myeloma (NDMM).

Read More

Translating Outcomes in Metastatic Colorectal Cancer (mCRC)

Translating Outcomes in Metastatic Colorectal Cancer (mCRC)

Tanios Bekaii -Saab, MD
December 20th 2023
Article

In this companion article, Dr Tanios Bekaii-Saab provides insights into effective management of patients with metastatic colorectal cancer.

Read More

Breast cancer diagram

Managing HER2+ Early Breast Cancer: A Focus on Target Therapy

December 19th 2023
Article

Read More

Sandra M. Swain, MD, FACP, FASCO, an expert on breast cancer

Managing HER2+ Early Breast Cancer: Insights and Future Horizons

Sandra M. Swain, MD, FACP, FASCO
November 28th 2023
Article

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.

Read More